John Morser

Dr. John Morser

orcid

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 May 2016 in Obesity
Verified
Journal Article
Open access
PDF file
SCShwu‐Shin Chang
Shwu‐Shin Chang
DEDan Eisenberg
Dan Eisenberg
LZLei Zhao
Lei Zhao
CAChristopher Adams
Christopher Adams
RLRyan Leib
Ryan Leib
LLLawrence Leung
Lawrence Leung
Objective: Chemerin is an inflammatory adipokine, whose activity is regulated by successive proteolytic cleavages at its C‐terminus. It is secreted as an inactive precursor (chem163S); cleavage at Lys158 converts it to chem158K with modest activity. Chem157S is the most potent form and chem155A is inactive. The aim of this study was to determine if chemerin was activated in samples from patients with obesity.Methods: Using specific ELISAs for different chemerin forms and a pan‐chemerin ELISA, chemerin forms in human obesity were characterized.Results: Plasma chemerin from patients with obesity (BMI 44.3 ± 1.3 kg/m2, n = 29) was significantly higher than in lean controls (BMI 20.9 ± 0.7 kg/m2, n = 10) (160 ± 11 vs. 76.2 ± 5.5 ng/mL, respectively, P < 0.0001). This increase in chemerin was due to increased previously unattributed chemerin, with further C‐terminal truncation demonstrated by mass spectrometry, accounting for ∼35% of total plasma chemerin. Chemerin forms in adipose tissue showed a different profile, with minimal chem163S and significant levels of chem157S. Chem155A was present in omental but not in subcutaneous adipose tissue. Unattributed chemerin forms were undetectable in adipose tissue.Conclusions: Chemerin is activated in adipose tissue of subjects with obesity, and further C‐terminal processing occurs during the disposition of chemerin from adipose tissue, resulting in substantial levels of novel degraded forms in plasma that correlate with obesity.

1 May 2010 in Journal of Thrombosis and Haemostasis
Verified
Journal Article
Closed access
PDF file
JMJohn Morser
John Morser
Esteban C. GabazzaEsteban C. Gabazza
Esteban C. Gabazza
TMT. Myles
T. Myles
LLL. L. K. Leung
L. L. K. Leung

1 March 2012 in Current Drug Targets
Verified
Journal Article
Closed access
PDF file
JMJohn Morser
John Morser
Thrombomodulin (TM) is a type 1 membrane bound glycoprotein that has a C-type lectin domain at its Nterminus, 6 copies of the epidermal growth factor-like (EGF) motif and serine/threonine rich domain carrying a glycosoaminoglycan external to the membrane. TM binds thrombin changing thrombin's substrate specificity from procoagulant and pro-inflammatory to anti-coagulant and anti-inflammatory because of the activation of protein C (PC) and thrombin-activatable fibrinolysis inhibitor (TAFI). Thrombin's anion binding site 1 binds to TM's EGF domains 5 and 6. EGF4 is required for PC activation and EGF3 and 4 for TAFI activation in addition to EGF56. The X-ray structure of thrombin bound to TM has been solved and shows few major alterations in the active site of thrombin. The lectin domain can bind high mobility group box protein 1 (HMGB1) and a sugar, Lewisy. TM's lectin domain behaves as an antagonist to HMGB1 endowing it with intrinsic anti-inflammatory activity. Treatment of dendritic cells with TM converts them from immunogenic to tolerogenic. TM is necessary for maintenance of pregnancy as well as prevention of coagulation throughout life. Soluble TM has been developed as an anticoagulant possessing favorable pharmacokinetics that has been approved for treatment of disseminated intravascular coagulation in Japan.

8 June 2018 in Journal of Thrombosis and Haemostasis
Verified
Journal Article
Closed access
PDF file
LLL.L.K. Leung
L.L.K. Leung
JMJohn Morser
John Morser

1 November 2011 in Journal of Biological Chemistry
Verified
Journal Article
Open access
PDF file
YYYasuto Yamaguchi
Yasuto Yamaguchi
XDXiao-Yan Du
Xiao-Yan Du
LZLei Zhao
Lei Zhao
JMJohn Morser
John Morser
LLLawrence L. K. Leung
Lawrence L. K. Leung
Chemerin is a chemoattractant involved in innate and adaptive immunity as well as an adipokine implicated in adipocyte differentiation. Chemerin circulates as an inactive precursor in blood whose bioactivity is closely regulated through proteolytic processing at its C terminus. We developed methodology for production of different recombinant chemerin isoforms (chem163S, chem157S, and chem155A) which allowed us to obtain large quantities of these proteins with purity of >95%. Chem158K was generated from chem163S by plasmin cleavage. Characterization by mass spectrometry and Edman degradation demonstrated that both the N and C termini were correct for each isoform. Ca2+ mobilization assays showed that the EC50 values for chem163S and chem158K were 54.2 ± 19.9 nm and 65.2 ± 13.2 nm, respectively, whereas chem157S had a ∼50-fold higher potency with an EC50 of 1.2 ± 0.7 nm. Chem155A had no agonist activity and weak antagonist activity, causing a 50% reduction of chem157S activity at a molar ratio of 100:1. Similar results were obtained in a chemotaxis assay. Because chem158K is the dominant form in cerebrospinal fluid from patients with glioblastoma (GBM), we examined the significance of chemerin in GBM biology. In silico analysis showed chemerin mRNA was significantly increased in tissue from grade III and IV gliomas. Furthermore, U-87 MG cells, a human GBM line, express the chemerin receptors, chemokine-like receptor 1 and chemokine receptor-like 2, and chem157S triggered Ca2+ flux. This study emphasized the necessity of appropriate C-terminal proteolytic processing to generate the likely physiologic form of active chemerin, chem157S, and suggested a possible role in malignant GBM.

1 November 2011 in Journal of Biological Chemistry
Verified
Journal Article
Open access
PDF file
LZLei Zhao
Lei Zhao
YYYasuto Yamaguchi
Yasuto Yamaguchi
SSShadi Sharif
Shadi Sharif
XDXiao-Yan Du
Xiao-Yan Du
JSJason J. Song
Jason J. Song
LLLawrence L. K. Leung
Lawrence L. K. Leung
Chemerin is a chemoattractant involved in immunity that may also function as an adipokine. Chemerin circulates as an inactive precursor (chem163S), and its activation requires proteolytic cleavages at its C terminus, involving proteases involved in coagulation, fibrinolysis, and inflammation. However, the key proteolytic steps in prochemerin activation in vivo remain to be established. Previously, we have shown that C-terminal cleavage of chem163S by plasmin to chem158K, followed by a carboxypeptidase cleavage, leads to the most active isoform, chem157S. To identify and quantify the in vivo chemerin isoforms in biological specimens, we developed specific ELISAs for chem163S, chem158K, and chem157S, using antibodies raised against peptides from the C terminus of the different chemerin isoforms. We found that the mean plasma concentrations of chem163S, chem158K, and chem157S were 40 ± 7.9, 8.1 ± 2.9, and 0.7 ± 0.8 ng/ml, respectively. The total level of cleaved and noncleaved chemerins in cerebrospinal fluids was ∼10% of plasma levels whereas it was elevated ∼2-fold in synovial fluids from patients with arthritis. On the other hand, the fraction of cleaved chemerins was much higher in synovial fluid and cerebrospinal fluid samples than in plasma (∼75%, 50%, and 18% respectively). Chem158K was the dominant chemerin isoform, and it was not generated by ex vivo processing, indicating that cleavage of prochemerin at position Lys-158, whether by plasmin or another serine protease, represents a major step in prochemerin activation in vivo. Our study provides the first direct evidence that chemerin undergoes extensive proteolytic processing in vivo, underlining the importance of measuring individual isoforms.